Zydus-XOMA announce IL-2-based IO licensing agreement to treat cancer
Category: #health  By Saipriya Iyer  Date: 2020-03-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Zydus-XOMA announce IL-2-based IO licensing agreement to treat cancer

Zydus Cadila and XOMA Corporation have recently announced a licensing agreement to advance an IL-2-based IO (immune-oncology) drug candidate. The drug candidate combines Zydus’s (an innovation-driven Indian pharmaceutical company) IL-2 with XOMA’s (biotechnology company) novel anti-IL-2 monoclonal antibody.

Under the terms of the licensing agreement, Zydus will advance the new immune-oncology drug candidate through various formal clinal trials. By collaborating with XOMA, the company will develop the new IO candidate through the human proof-of-concept. The two companies may potentially receive pre-defined shares from the future proceeds of the licensing & commercialization activities. Zydus has obtained exclusive rights to develop & commercialize the therapy in Mexico, Brazil, and India, among other emerging markets, where XOMA could indulge in commercial sales and receive single-to-double-digit royalties in these territories.

According to the statement made by Dr. Sharvil Patel, Zydus group’s Managing Director, Interleukin-2 is expected to actively support IO-based therapies for the treatment of cancer. The licensing agreement will prove beneficial for both the companies as the combination of IL-2 of Zydus and anti-IL-2 monoclonal antibody of XOMA will be a great strategic fit to introduce an efficacious and safe cancer medicine. This strategy will significantly address the cancer patients’ unmet needs due to drug limitations.

As per XOMA’s Chief Executive Officer, Jim Neal, Zydus has become the ideal partner of the company for clinical development of anti-cancer drug candidates, as the combination of IL-2 and novel monoclonal antibody can potentially turn the immune system of patients against the cancer cells. IL-2 developed by Zydus has been recognized as an effective anti-tumor agent for a while; however, has limited utility due to toxicity in multiple organ systems. With an aim to address this limitation, XOMA has recently developed unique antibodies that promote the action of IL-2 to the cytotoxic immune effector T cells specifically, for anti-tumor activity. Through this, it will simultaneously limit the undesirable stimulation of immunosuppressive T cells as well as minimize the unwanted side-effects.

Source credit:

https://www.wallstreet-online.de/nachricht/12254777-zydus-and-xoma-announce-il-2-based-immuno-oncology-therapy-licensing-agreement



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
By Saipriya Iyer

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among childre...

Medtronic to turn Hyderabad into R&D hub with $160.3M investment
Medtronic to turn Hyderabad into R&D hub with $160.3M investment
By Saipriya Iyer

Medtronic, a medical device company, has reportedly announced an investment of Rs.1,200 crore ($160.3 million) to turn Hyderabad into its R&D center outside the U.S. The investment has been planned by the company s...

Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
Toshiba exits PC business & transfers remaining 19.1% stake to Sharp
By Saipriya Iyer

Toshiba, a Japanese multinational conglomerate, has reportedly made an exit from the laptop business and transferred its remaining minority stake in the PC business to Sharp. This will mark the company’s terminat...